Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 407-414

  Kolevzon, Alexander ^a   Mathewson, Karen A ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL DISCOMFORT; AGGRESSION; AGGRESSIVENESS; AGITATION; AKATHISIA; ALOPECIA; ANOREXIA; ANXIETY; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL TRIAL; COMPULSION; CRYING; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DYSKINESIA; HEADACHE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; LIP DISEASE; MACULOPAPULAR RASH; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PSYCHOTHERAPY; RESTLESSNESS; REVIEW; RHINITIS; SCREAMING SYNDROME; SEDATION; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TINNITUS; TREATMENT OUTCOME; VERTIGO; VIVID DREAM; WEIGHT GAIN; YAWNING;

EID: 33645754287     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0311     Document Type: Review

References (37)

1. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr 1996;8:348-354
2. Chugani DC. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 2002;7(suppl 2):S16-S17
3. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961;58:315-320
4. Ritvo ER, Yuwiler A, Geller E, et al. Increased blood serotonin and platelets in early infantile autism. Arch Gen Psychiatry 1970;23:566-572
5. Takahashi S, Kanai H, Miyamoto Y. Reassessment of elevated serotonin levels in blood platelets in early infantile autism. J Autism Child Schizophr 1976;6:317-326
6. Hanley HG, Stahl SM, Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 1977;34:521-531
7. Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987;28:885-900
8. Cook EH, Leventhal BL, Heller W, et al. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci 1990;2:268-274
9. Leventhal BL, Cook EH, Morford M, et al. Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord 1990;20:499-511
10. Leboyer M, Philippe A, Bouvard M, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry 1999;45:158-163
11. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999;45:287-295
12. Piven J, Tsai GC, Nehme E, et al. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord 1991;21:51-59
13. Murphy DL, Lerner A, Rudnick G, et al. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004;4:109-123
14. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624
15. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1483-1487
16. Greenberg BD, Tolliver TJ, Huang SJ, et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999;88:83-87
17. Cook EH, Courchesne R, Lord R, et al. Evidence of linkage between the serotonin transporter and autism. Mol Psychiatry 1997;2:247-250
18. Klauck SM, Poustka F, Benner A, et al. Serotonin transporter (5-HTT) gene variants associated with autism. Hum Mol Genet 1997;6:2233-2238
19. Yirniya N, Pilowski T, Nemanov L. Evidence for an association with the serotonin transporter region polymorphism and autism. Am J Med Genet 2001;105:381-386
20. McCauley JL, Olson LM, Dowd M, et al. Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am J Med Genet 2004;127:104-112
21. Tordjman S, Gutknecht L, Carlier M, et al. Role of serotonin transporter gene (SLC6A4) region in autistic disorder. Mol Psychiatry 2002;7:278-288
22. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-589
23. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 2001;4:119-125
24. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-1008
25. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005;44:343-348
26. Namerow LB, Prakash T, Bostic JQ, et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003;24:104-108
27. Martin A, Koenig K, Anderson GM, et al. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 2003;33:77-85
28. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002;44:652-659
29. DeLong RG, Teague LA, Kamran MM. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-562
30. McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-66
31. Steingard RJ, Zimnitzky B, DeMaso DR, et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9-15
32. Hellings JA, Kelley L, Gabrielli WF, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-336
33. Cook EH, Rowlett R, Jaselinkis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-745
34. Fatemi SH, Realmuto GM, Khan L, et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-307
35. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000;30:427-435
36. Strauss WL, Unis AS, Cowan C, et al. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 2002;159:755-760
37. Hollander E, Phillips A, King BH, et al. Impact of recent findings on study design of future autism clinical trials. CNS Spectr 2004;9:49-56